Detection of Protein Folding Defects Caused by BRCA1-BRCT Truncation and Missense Mutations
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Most cancer-associated BRCA1 mutations identified to date result in the premature translational termination of the protein, highlighting a crucial role for the C-terminal, BRCT repeat region in mediating BRCA1 tumor suppressor function. However, the molecular and genetic effects of missense mutations that map to the BRCT region remain largely unknown. Using a protease-based assay, we directly assessed the sensitivity of the folding of the BRCT domain to an extensive set of truncation and single amino acid substitutions derived from breast cancer screening programs. The protein can tolerate truncations of up to 8 amino acids, but further deletion results in drastic BRCT folding defects. This molecular phenotype can be correlated with an increased susceptibility to disease. A cross-validated computational assessment of the BRCT mutation data base suggests that as much as half of all BRCT missense mutations contribute to BRCA1 loss of function and disease through protein-destabilizing effects. The coupled use of proteolytic methods and computational predictive methods to detect mutant BRCA1 conformations at the protein level will augment the efficacy of current BRCA1 screening protocols, especially in the absence of clinical data that can be used to discriminate deleterious BRCT missense mutations from benign polymorphisms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A superfamily of conserved domains in DNA damage‐ responsive cell cycle checkpoint proteins
Bork, P., Hofmann, K., Bucher, P., Neuwald, A. F., Altschul, S. F., & Koonin, E. V. (1997) · The FASEB Journal · doi:10.1096/fasebj.11.1.9034168 · Cited by 746
Cantor, S. B., Bell, D. W., Ganesan, S., Kass, E. M., Drapkin, R., Grossman, S., Wahrer, D. C. R., Sgroi, D. C., Lane, W. S., Haber, D. A., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00304-x · Cited by 674
Genetic Analysis of BRCA1 Function in a Defined Tumor Cell Line
Scully, R., Ganesan, S., Vlasakova, K., Chen, J., Socolovsky, M., & Livingston, D. M. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80238-5 · Cited by 359
Cited by
Putnam, C. D., Hammel, M., Hura, G. L., & Tainer, J. A. (2007) · Quarterly Reviews of Biophysics · doi:10.1017/s0033583507004635 · Cited by 1,184
Homologous Recombination and Human Health: The Roles of BRCA1, BRCA2, and Associated Proteins
Prakash, R., Zhang, Y., Feng, W., & Jasin, M. (2015) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a016600 · Cited by 869
“However, mutations in the BRCT domain often result in destabilization of the mu- tant BRCA1 protein (Williams and Glover 2003; Williams et al. 2003; Lee et al. 2010) and thus impair RAD51 loading despite an intact PALB2interaction domain (Johnson et al. 2013).”
BackgroundHassa, P. (2008) · Frontiers in Bioscience · doi:10.2741/2909 · Cited by 584
Chen, L., Nievera, C. J., Lee, A. Y.-L., & Wu, X. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m710245200 · Cited by 424
Filamentous Phage Display in the New Millennium
Kehoe, J. W., & Kay, B. K. (2005) · Chemical Reviews · doi:10.1021/cr000261r · Cited by 413
Patterns and functional implications of rare germline variants across 12 cancer types
Lu, C., Xie, M., Wendl, M. C., Wang, J., McLellan, M. D., Leiserson, M. D. M., Huang, K.-L., Wyczalkowski, M. A., Jayasinghe, R., Banerjee, T., et al. (2015) · Nature Communications · doi:10.1038/ncomms10086 · Cited by 296
Wang, Y., Bernhardy, A. J., Cruz, C., Krais, J. J., Nacson, J., Nicolas, E., Peri, S., van der Gulden, H., van der Heijden, I., O'Brien, S. W., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0186 · Cited by 269
Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance
Johnson, N., Johnson, S. F., Yao, W., Li, Y.-C., Choi, Y.-E., Bernhardy, A. J., Wang, Y., Capelletti, M., Sarosiek, K. A., Moreau, L. A., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1305170110 · Cited by 265
Structural basis of phosphopeptide recognition by the BRCT domain of BRCA1
Williams, R. S., Lee, M. S., Hau, D. D., & Glover, J. N. M. (2004) · Nature Structural & Molecular Biology · doi:10.1038/nsmb776 · Cited by 230
Self-citationKumaraswamy, E., & Shiekhattar, R. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00961-07 · Cited by 110
“Cancer-causing missense mutations have been identified at the interface between the two BRCT repeats of BRCA1, which destabilize the structure (39, 40).”
BackgroundGlover, J. N. M. (2006) · Familial Cancer · doi:10.1007/s10689-005-2579-z · Cited by 57
“The variants D1692Y, C1697R, R1699W, A1708E, S1715R, P1749R, and M1775R all appear to be associated with an increased risk of breast cancer, whileM1652I appears to be a benign polymorphism (reviewed in [12]).”
BackgroundMethodInfluentialSelf-citation
Metadata
- Authors
- Williams, R. S., Chasman, D. I., Hau, D. D., Hui, B., Lau, A. Y., & Glover, J. N. M.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2003-12
- Volume
- 278
- Issue
- 52
- Pages
- 53007-53016
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2170278099
- Cited by
- 137
- References
- 3
- FWCI
- 3.85
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.